Suppr超能文献

心力衰竭中心脏与肿瘤相互作用的见解

Insights Into Heart-Tumor Interactions in Heart Failure.

作者信息

Caller Tal, Moore Kathryn J, Lehmann Lorenz H, Wu Sean M, Leor Jonathan

机构信息

Neufeld and Tamman Cardiovascular Research Institutes, Faculty of Medical and Health Sciences, Tel Aviv University, Israel (T.C., J.L.).

Lev Leviev Cardiovascular and Thoracic Center, Sheba Medical Center, Tel Hashomer, Israel (T.C., J.L.).

出版信息

Circ Res. 2025 May 23;136(11):1262-1285. doi: 10.1161/CIRCRESAHA.124.325490. Epub 2025 May 22.

Abstract

Heart failure (HF) often coexists with cancer. Beyond the known cardiotoxicity of some cancer treatments, HF itself has been associated with increased cancer incidence. The 2 conditions share common risk factors, mechanisms, and interactions that can worsen patient outcomes. The bidirectional relationship between HF and cancer presents a complex interplay of factors that are not fully understood. Recent preclinical evidence suggests that HF may promote tumor growth via the release of protumorigenic factors from the injured heart, revealing HF as a potentially protumorigenic condition. Our review discusses the biological crosstalk between HF and cancer, emphasizing the impact of HF on tumor growth, with inflammation, and modulating the immune system as central mechanisms. We further explore the clinical implications of this connection and propose future research directions. Understanding the mechanistic overlap and interactions between HF and cancer could lead to new biomarkers and therapies, addressing the growing prevalence of both conditions and enhancing approaches to diagnosis, prevention, and treatment.

摘要

心力衰竭(HF)常与癌症并存。除了某些癌症治疗已知的心脏毒性外,HF本身也与癌症发病率增加有关。这两种疾病具有共同的危险因素、机制和相互作用,可使患者预后恶化。HF与癌症之间的双向关系呈现出一种尚未完全了解的复杂因素相互作用。最近的临床前证据表明,HF可能通过受损心脏释放促肿瘤因子来促进肿瘤生长,揭示HF是一种潜在的促肿瘤状态。我们的综述讨论了HF与癌症之间的生物学相互作用,强调HF对肿瘤生长的影响,其中炎症和调节免疫系统是核心机制。我们进一步探讨了这种联系的临床意义,并提出了未来的研究方向。了解HF与癌症之间的机制重叠和相互作用可能会产生新的生物标志物和治疗方法,解决这两种疾病日益普遍的问题,并加强诊断、预防和治疗方法。

相似文献

1
Insights Into Heart-Tumor Interactions in Heart Failure.
Circ Res. 2025 May 23;136(11):1262-1285. doi: 10.1161/CIRCRESAHA.124.325490. Epub 2025 May 22.
2
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications.
Curr Oncol Rep. 2020 Dec 2;23(1):7. doi: 10.1007/s11912-020-00990-z.
3
Cancer Development and Progression in Patients with Heart Failure.
Curr Heart Fail Rep. 2024 Dec;21(6):515-529. doi: 10.1007/s11897-024-00680-y. Epub 2024 Sep 28.
6
Cancer and heart disease: associations and relations.
Eur J Heart Fail. 2019 Dec;21(12):1515-1525. doi: 10.1002/ejhf.1539. Epub 2019 Jul 18.
8
Linking Heart Failure to Cancer: Background Evidence and Research Perspectives.
Circulation. 2018 Aug 14;138(7):735-742. doi: 10.1161/CIRCULATIONAHA.118.033603.
9
An emerging epidemic: cancer and heart failure.
Clin Sci (Lond). 2017 Jan 1;131(2):113-121. doi: 10.1042/CS20160412.
10
Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.
Eur J Heart Fail. 2018 May;20(5):879-887. doi: 10.1002/ejhf.1165. Epub 2018 Feb 21.

引用本文的文献

1
Interorgan Crosstalk in Heart Failure and Cardiometabolic Diseases: A Compendium.
Circ Res. 2025 May 23;136(11):1167-1169. doi: 10.1161/CIRCRESAHA.125.326720. Epub 2025 May 22.

本文引用的文献

1
Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial.
Nat Med. 2025 Apr;31(4):1120-1124. doi: 10.1038/s41591-024-03486-6. Epub 2025 Jan 24.
2
Atherosclerotic Cardiovascular Diseases Are Associated With Incident Metastatic and Nonmetastatic Cancer.
JACC CardioOncol. 2024 Oct 1;6(6):949-961. doi: 10.1016/j.jaccao.2024.07.020. eCollection 2024 Dec.
3
Ischemic Heart Disease in the Cancer Population: Trends, Outcomes, Epidemiology, and Challenges in Diagnosis and Treatment.
Cardiol Clin. 2025 Feb;43(1):57-67. doi: 10.1016/j.ccl.2024.08.001. Epub 2024 Sep 27.
4
Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.
JACC CardioOncol. 2024 Sep 24;6(5):631-654. doi: 10.1016/j.jaccao.2024.07.017. eCollection 2024 Oct.
5
Genetic inference and single cell expression analysis of potential targets in heart failure and breast cancer.
J Cancer Res Clin Oncol. 2024 Oct 26;150(10):479. doi: 10.1007/s00432-024-06010-y.
6
Ponsegromab for the Treatment of Cancer Cachexia.
N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14.
7
Clinical trials in-a-dish for cardiovascular medicine.
Eur Heart J. 2024 Oct 21;45(40):4275-4290. doi: 10.1093/eurheartj/ehae519.
9
Targeting the tumour vasculature: from vessel destruction to promotion.
Nat Rev Cancer. 2024 Oct;24(10):655-675. doi: 10.1038/s41568-024-00736-0. Epub 2024 Aug 29.
10
Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.
ESC Heart Fail. 2024 Dec;11(6):4201-4208. doi: 10.1002/ehf2.14955. Epub 2024 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验